MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
Mazzera L, Abeltino M, Lombardi G, Cantoni AM, Jottini S, Corradi A, Ricca M, Rossetti E, Armando F, Peli A, Ferrari A, Martinelli G, Scupoli MT, Visco C, Bonifacio M, Ripamonti A, Gambacorti-Passerini C, Bonati A, Perris R, Lunghi P.
Mazzera L, et al.
Leukemia. 2023 Aug;37(8):1671-1685. doi: 10.1038/s41375-023-01940-x. Epub 2023 Jun 29.
Leukemia. 2023.
PMID: 37386079
Free PMC article.